HIV Clinical Trial
HIV was once a fatal diagnosis, but due to treatment advances it is no longer a death
sentence. Today, HIV-infected adults face a new challenge to their health; they are
developing cardiovascular disease (CVD) earlier and more frequently than those not
HIV-infected. Reasons for this include toxic effects of HIV medications and activation of the
immune system. Preventing cardiovascular disease in HIV-infected adults will help them live
healthier lives; however, there is a lack evidence to help us to achieve this goal. Exercise
prevents cardiovascular disease, but it is often not addressed in HIV care, due, in part, to
a lack of practical interventions targeting this population. This study will address this
problem by testing an intervention to improve and maintain exercise in HIV-infected adults.
This study will examine the impact of an innovative and sustainable intervention, adapted to
the unique medical and psychosocial needs of HIV-infected adults, called SystemCHANGE-HIV. It
consists of six sessions to help redesign an individual's environment and routines to
increase exercise.This is a randomized trial in which half of the subjects will participate
in the intervention and half will participate in a control condition. Measures include
assessments of exercise, fitness, and the markers of cardiovascular health before and after
the intervention to see if, and how, they changed.
Emerging evidence suggests that HIV infection is associated with a 1.5-2-fold higher risk of
cardiovascular disease. This may be due, in part, to an increase in cardiometabolic risk
factors related to the toxic effects of HIV medications, immune activation, and chronic
inflammation. Interventions to prevent cardiovascular disease, accounting for the unique
medical and psychosocial needs of HIV-infected adults, are needed.
Exercise has been shown to improve cardiometabolic risk and decrease cardiovascular disease.
It has further been shown to improve cardiometabolic risk factors in some groups of
HIV-infected adults in brief and intensely supervised trials. However, how to sustain
exercise in this population with practical and scalable interventions that can be implemented
in the home setting (i.e., free-living exercise) is unknown. The purpose of this is to test a
novel, evidence-based intervention, SystemCHANGE-HIV, which holds promise for improving
exercise in HIV-infected adults.
SystemCHANGE-HIV is a new behavior-change program that is based on a systems re-design model,
in which the individual's daily routines are composed of a set of habits (behaviors) that can
be changed. The intervention engages participants in a series of self-designed experiments to
test ways to change their behaviors. The program involves six weekly group sessions to teach
behavior-changing and exercise-improvement strategies, followed by monthly telephone booster
sessions to encourage maintenance of beneficial effects. SystemCHANGE has significantly
improved exercise adherence and cardiovascular risk factors in HIV-uninfected adults. The
specific aims of our study are to (1) evaluate the 3-month and 6-month effects of
SystemCHANGE-HIV on the amount and intensity of free-living exercise, and (2) describe the
impact of SystemCHANGE-HIV on fitness (VO2 max) and cardiometabolic health.
To accomplish these aims, this is a longitudinal, randomized controlled trial (n=105)
comparing the effects SystemCHANGE-HIV to those of an attention-control condition. The
outcomes will be assessed for efficacy using biological and behavioral evaluations including:
actigraphy, fitness assessments, and clinical laboratory assessments.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06162897 -
Case Management Dyad
|
N/A | |
Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
Completed |
NCT02528773 -
Efficacy of ART to Interrupt HIV Transmission Networks
|
||
Active, not recruiting |
NCT05454839 -
Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
|
||
Recruiting |
NCT05322629 -
Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women
|
N/A | |
Completed |
NCT02579135 -
Reducing HIV Risk Among Adolescents: Evaluating Project HEART
|
N/A | |
Active, not recruiting |
NCT01790373 -
Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence
|
N/A | |
Not yet recruiting |
NCT06044792 -
The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
|
||
Completed |
NCT04039217 -
Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM
|
Phase 4 | |
Active, not recruiting |
NCT04519970 -
Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK)
|
N/A | |
Completed |
NCT04124536 -
Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women
|
N/A | |
Recruiting |
NCT05599581 -
Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health
|
N/A | |
Active, not recruiting |
NCT04588883 -
Strengthening Families Living With HIV in Kenya
|
N/A | |
Completed |
NCT02758093 -
Speed of Processing Training in Adults With HIV
|
N/A | |
Completed |
NCT02500446 -
Dolutegravir Impact on Residual Replication
|
Phase 4 | |
Completed |
NCT03805451 -
Life Steps for PrEP for Youth
|
N/A | |
Active, not recruiting |
NCT03902431 -
Translating the ABCS Into HIV Care
|
N/A | |
Completed |
NCT00729391 -
Women-Focused HIV Prevention in the Western Cape
|
Phase 2/Phase 3 | |
Recruiting |
NCT05736588 -
Elimisha HPV (Human Papillomavirus)
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 |